These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26413747)

  • 1. Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.
    Neogi U; Engelbrecht S; Claassen M; Jacobs GB; van Zyl G; Preiser W; Sonnerborg A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):80-4. PubMed ID: 26413747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness.
    van Domselaar R; Njenda DT; Rao R; Sönnerborg A; Singh K; Neogi U
    J Virol; 2019 May; 93(9):. PubMed ID: 30760577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.
    Aralaguppe SG; Winner D; Singh K; Sarafianos SG; Quiñones-Mateu ME; Sönnerborg A; Neogi U
    J Med Virol; 2017 Jan; 89(1):106-111. PubMed ID: 27328744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa.
    Sharma S; Aralaguppe SG; Abrahams MR; Williamson C; Gray C; Balakrishnan P; Saravanan S; Murugavel KG; Solomon S; Ranga U
    BMC Infect Dis; 2017 Jan; 17(1):95. PubMed ID: 28118816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.
    Neogi U; Rao SD; Bontell I; Verheyen J; Rao VR; Gore SC; Soni N; Shet A; Schülter E; Ekstrand ML; Wondwossen A; Kaiser R; Madhusudhan MS; Prasad VR; Sonnerborg A
    AIDS; 2014 Sep; 28(15):2319-22. PubMed ID: 25102091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.
    Ojesina AI; Chaplin B; Sankalé JL; Murphy R; Idigbe E; Adewole I; Ekong E; Idoko J; Kanki PJ
    AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1167-74. PubMed ID: 18729771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
    Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
    Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
    Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
    J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
    Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.